Quotient Clinical Announces ADME Success in Oncology
News Apr 02, 2015
Quotient Clinical has announced contract wins for three further OncoADME programs to support clinical mass balance/ADME investigations in cancer patients. Two of the programs will be undertaken on behalf of US-based biotech organizations and the third is for a top 10 global pharmaceutical company.
Quotient’s OncoADME service takes advantage of the company’s real-time adaptive manufacturing approach to supply 14C radiolabelled drug products to specialist oncology clinics globally. Drug products are manufactured on a ‘per patient’ basis and supplied to the clinic for dosing within two weeks of patient enrolment.
This streamlined approach tailors drug product manufacturing to patient recruitment, reducing overall project costs and enabling the management and control of any issues related to instability of the 14C radiolabel.
Mark Egerton, CEO of Quotient Clinical, commented: “We are extremely pleased with how the OncoADME service has been accepted by our customers. Our ability to manufacture drug products in real time, and synchronize manufacturing activities with patient recruitment, is proving an effective way of reducing drug development costs and improving efficiency. Over recent years we have become one of the leading global providers of human ADME programs in healthy volunteers, and we are now able to offer oncology drug development teams the option to undertake these investigations directly in cancer patients”.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE